Last updated on April 2020

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Brief description of study

An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with relapsed or refractory malignancies.

Clinical Study Identifier: NCT03236857

Find a site near you

Start Over

Primary Children's /ID# 164399

Salt Lake City, UT United States
  Connect »

Royal Victoria Infirmary, Newc /ID# 162938

Newcastle Upon Tyne, United Kingdom
  Connect »